This study investigates the therapeutic potential of a Schiff base compound (phenolphthalein derivate appended 2-furoic hydrazide) using in silico drug similarity predictions, molecular docking, and in vitro antimicrobial and cytotoxicity assays. Despite low solubility (LogS -5.564) and gastrointestinal absorption challenges, the compound demonstrates moderate lipophilicity (LogP 3.459) and strong binding affinity to mycobacterial targets, including enoyl-acyl carrier protein reductase (InhA) in Mycobacterium tuberculosis (-9.11 kcal/mol), suggesting antimicrobial potential. In vitro antimicrobial assays show significant activity against Gram-positive (Bacillus cereus, Bacillus licheniformis) with a minimum inhibitory concentration (MIC) of 0.1 mM. The compound is bactericidal against Gram-positive bacteria and bacteriostatic against Gram-negative bacteria. Cytotoxicity tests on liver cancer (Mahlavu), normal liver (THLE2), and breast cancer (MCF7) cell lines reveal dose-dependent decreases in cell viability, with IC50 values of 8.77 ± 0.39 μM (Mahlavu), 10.78 ± 0.43 μM (THLE2), and 19.25 ± 2.97 μM (MCF7), indicating selective anticancer activity, particularly in liver cells. While the compound shows promising antimicrobial and anticancer effects, concerns about bioavailability, drug-drug interactions, and toxicity require further optimization. Enhancing its pharmacokinetic properties and investigating metal complexes could improve its therapeutic potential for clinical use.